InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,618.26
(
-0.29%
)
US TECH 100
19,022.00
(
0.44%
)
Dow Jones
41,503.10
(
-0.25%
)
Brent Oil
73.15
(
1.06%
)
Bitcoin
61,983.23
(
0.51%
)
Post# of 253151
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Carl Chris

Send PM Follow Ignore
Followers 0
Posts 8
Boards Moderated 0
Alias Born 09/20/2013

Carl Chris

Re: None

Friday, 12/19/2014 3:35:51 AM

Friday, December 19, 2014 3:35:51 AM

Post# of 253151
Gilead bought BTK inhibitor from ONO

http://www.gilead.com/news/press-releases/2014/12/ono-and-gilead-announce-exclusive-license-agreement-to-develop-btk-inhibitor-ono4059-for-the-treatment-of-bcell-malignancies-and-other-diseases

This is the 4th acquisition to build up the hematology pipeline. Determined but the position is still in danger. After the black box in Idelalisib and the failure of GS-9820, maybe they need a Pharmasset-like move to regain the lead position.

BTW, GS-9901, another PI3Kd, planed for ph1 but missed the starting date already.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up